Screener
ImmunityBio, Inc. IBRX Income Tax
Income Tax at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other expense, net | (5,917) | (41) |
| Total other expense, net | (562,997) | (65,471) |
| Loss before income taxes and noncontrolling interest | (632,788) | (129,900) |
| Income tax (expense) benefit | (9) | 234 |
| Net loss | (632,797) | (129,666) |
| Net loss attributable to noncontrolling interests, net of tax | (15) | (20) |
| Net loss attributable to ImmunityBio common stockholders | $(632,782) | $(129,646) |
| Net loss per ImmunityBio common share – basic and diluted | $(0.62) | $(0.15) |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s income tax?
- ImmunityBio, Inc. (IBRX) reported income tax of $9K in Q1 2026.
- How has ImmunityBio, Inc.'s income tax changed year-over-year?
- ImmunityBio, Inc.'s income tax increased by 103.8% year-over-year, from -$234K to $9K.
- What is the long-term trend for ImmunityBio, Inc.'s income tax?
- Over 4 years (2021 to 2025), ImmunityBio, Inc.'s income tax has grown at a 96.8% compound annual growth rate (CAGR), from $9K to -$135K.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.
Ask your AI about ImmunityBio, Inc.'s income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude